Egorov E A, Stavitskaia T V
Vestn Oftalmol. 1998 May-Jun;114(3):3-4.
Tolerance and efficacy of a new combined antiglaucoma drug proxopheline (1% proxodolol and 0.25% clopheline) is assessed. Studies in 43 patients (63 eyes) with open-angle glaucoma showed that a single instillation of the drug decreases intraocular pressure in 1 h and in 93% of patients the hypotensive effect persists for up to 24 h. Prolonged (4 weeks) use of proxopheline resulted in normalization of intraocular pressure in 90% of treated eyes. The main side effect was dryness in the mouth (30%). The hypotensive effect of proxopheline is superior to that of proxodolol, but it involves a higher incidence of side effects, caused by clopheline--another component of proxopheline.
评估了一种新型抗青光眼联合药物普罗索啡啉(1%普洛多洛尔和0.25%氯非林)的耐受性和疗效。对43例(63只眼)开角型青光眼患者的研究表明,单次滴注该药物可在1小时内降低眼压,93%的患者降压效果可持续长达24小时。长期(4周)使用普罗索啡啉可使90%的治疗眼眼压恢复正常。主要副作用是口干(30%)。普罗索啡啉的降压效果优于普洛多洛尔,但副作用发生率更高,这是由普罗索啡啉的另一种成分氯非林引起的。